Johnson and Johnson have reportedly developed a single-shot COVID-19 vaccine which the company has reported to be 66% against moderate and severe illness in the third phase of their global trials.
BREAKING: Johnson & Johnson's one-dose vaccine seems to protect against COVID-19, but not as well as some two-shot rivals. https://t.co/q2lAsGaVjE
— The Associated Press (@AP) January 29, 2021
They went on to report that the vaccine is 85% effective against the most serious symptoms, with many countries around the world in desperate need for more vaccines.
As stated by Johnson & Johnson’s vaccine branch, Janssen, the vaccine’s 85% efficacy prevents severe diseases, that is, ones that “make you feel particularly sick at home, or may go to the hospital, or worse..”
#MaltaDaily